These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11085710)

  • 1. Pumactant and poractant alfa in respiratory distress syndrome.
    Morley C
    Lancet; 2000 Aug; 356(9231):765; author reply 766. PubMed ID: 11085710
    [No Abstract]   [Full Text] [Related]  

  • 2. Pumactant and poractant alfa in respiratory distress syndrome.
    Wardhaugh AD; Matthes JW
    Lancet; 2000 Aug; 356(9231):765-6. PubMed ID: 11085711
    [No Abstract]   [Full Text] [Related]  

  • 3. Pumactant and poractant alfa surfactant treatment.
    Gillespie L; Madar J
    Lancet; 2000 Jul; 356(9224):167-8. PubMed ID: 10963277
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In response to mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Egan EA
    J Perinatol; 2013 Feb; 33(2):165-6. PubMed ID: 23361501
    [No Abstract]   [Full Text] [Related]  

  • 8. On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).
    Bancalari E
    Am J Perinatol; 2004 Jul; 21(5):307-9. PubMed ID: 15232767
    [No Abstract]   [Full Text] [Related]  

  • 9. Exogenous surfactant administration during the transport of premature infants.
    Riek KM
    Air Med J; 2004; 23(5):8-9. PubMed ID: 15337930
    [No Abstract]   [Full Text] [Related]  

  • 10. The 5 W's of surfactant for respiratory distress syndrome of the premature infant.
    Parmigiani S
    J Matern Fetal Neonatal Med; 2004 Nov; 16 Suppl 2():25-7. PubMed ID: 15590430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant replacement therapy: prophylaxis or treatment?
    Dunn MS
    Pediatrics; 1993 Jul; 92(1):148-50. PubMed ID: 8516063
    [No Abstract]   [Full Text] [Related]  

  • 12. Surfactant therapy in extremely premature infants.
    Merritt TA
    J Pediatr; 1994 Jul; 125(1):172-3; author reply 173-4. PubMed ID: 8021775
    [No Abstract]   [Full Text] [Related]  

  • 13. [Substitutive therapy with surfactants in premature infants with respiratory distress syndrome].
    Liberatore A; Carrera G; Calciolari G; Coccia C; Coppalini B; Fulconis F; Moro G; Scimone F; Villa G; Minoli I
    Ann Osp Maria Vittoria Torino; 1987-1988; 30():28-35. PubMed ID: 3334194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surfactant therapy in extremely premature infants.
    Bose C; McCaffrey M
    J Pediatr; 1994 Jul; 125(1):173; author reply 173-4. PubMed ID: 8021776
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Ramanathan R; Bhatia JJ; Sekar K; Ernst FR
    J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surfactant therapy of premature infants. Complications and mortality are reduced].
    Hjalmarson O
    Lakartidningen; 1993 Nov; 90(45):3938-40. PubMed ID: 8231562
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.
    Singh N; Hawley KL; Viswanathan K
    Pediatrics; 2011 Dec; 128(6):e1588-95. PubMed ID: 22123870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial.
    Ainsworth SB; Beresford MW; Milligan DW; Shaw NJ; Matthews JN; Fenton AC; Ward Platt MP
    Lancet; 2000 Apr; 355(9213):1387-92. PubMed ID: 10791521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surfactant-replacement therapy.
    Avery ME; Merritt TA
    N Engl J Med; 1991 Mar; 324(13):910-2. PubMed ID: 2000113
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation.
    Kattwinkel J; Bloom BT; Delmore P; Davis CL; Farrell E; Friss H; Jung AL; King K; Mueller D
    Pediatrics; 1993 Jul; 92(1):90-8. PubMed ID: 8516091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.